[Product].

Ningbo Fuda: It is planned to acquire no less than 45% of the equity of Jingxin Materials

Ningbo Fuda (600724) announced that the company signed the "Investment Cooperation Agreement with the shareholders of Jingxin Materials", intending to acquire no less than 45% of the shares of Jingxin Materials, and Hou Xiaobao, a shareholder of Jingxin Materials, entrusts or transfers no less than 6% of the voting rights to the company to ensure that the company has no less than 51% of the voting rights of Jingxin Materials. According to preliminary estimates, this transaction is expected to constitute a major asset restructuring. After the completion of this transaction, Jingxin Materials will become the company's holding subsidiary, and the company will enter the field of electronic special materials based on photovoltaic silver powder on the basis of the original two main businesses of commercial real estate and cement building materials, and will rely on its own resource advantages to achieve effective synergy with Jingxin Materials to help the company achieve industrial transformation breakthroughs and energy level improvement.

Yitai B shares: Stop promoting the 2 million tons/year coal indirect liquefaction demonstration project of Inner Mongolia Yitai Coal-to-Liquids Co., Ltd

Yitai B shares (900948) announced that based on the prudent judgment of the industry situation and the actual situation of the company, the company intends to stop promoting the 2 million tons/year coal indirect liquefaction demonstration project of Inner Mongolia Yitai Coal-to-Liquids Co., Ltd. The cessation of the 2 million tons of coal-to-liquid project will lead to the impairment of some of the company's assets, and the company will make asset impairment provisions for the relevant assets according to the evaluation report issued by a third-party intermediary, and the specific impairment amount is still uncertain. The matter still needs to be submitted to the general meeting of shareholders of the company for deliberation. The main reason for the cessation of the promotion: it is expected that the price of coal will continue to fall, the company plans to build two coal-to-liquid projects with a total investment of nearly 50 billion yuan, the large investment will occupy the company's funds for a long time, and the return on investment cycle of large-scale projects is longer, which poses a severe challenge to the company's financing ability, and the company is at the same time building two large-scale coal-to-liquid projects with greater economic risk.

[Performance].

China Duty Free Performance Express: Net profit in 2024 will decrease by 36.5% year-on-year

China Duty Free (601888) released a performance report, and in 2024, the company will achieve operating income of 56.492 billion yuan, a year-on-year decrease of 16.36%; net profit attributable to shareholders of listed companies was 4.263 billion yuan, down 36.50% year-on-year; Basic earnings per share: 2.06 yuan. During the reporting period, the company continued to cultivate the Hainan market, launched a new "duty-free +" shopping experience, and created a new pattern of in-depth integration and development of "culture, commerce, sports and tourism", and the duty-free market share of Hainan Islands increased by nearly 2 percentage points year-on-year. The revenue of duty-free stores at Beijing Airport (including Capital International Airport and Daxing International Airport) increased by more than 115% year-on-year, and the revenue from duty-free stores at Shanghai Airport (including Pudong International Airport and Hongqiao International Airport) increased by nearly 32% year-on-year.

Iceberg hot and cold: net profit in 2024 is expected to increase by 122.76%-143.01% year-on-year

Bingshan Cold & Hot (000530) announced that in 2024, it is expected to achieve a net profit attributable to shareholders of listed companies of 110 million yuan to 120 million yuan, a year-on-year increase of 122.76% to 143.01%. The company completed a major asset restructuring in November 2022, and the new subsidiaries brought more profit contributions during the reporting period; During the reporting period, the company completed the sale of the shares of Guotaijun Security Department, contributing about 51.38 million yuan to the company's net profit in 2024.

Zhongpet shares: net profit in 2024 is expected to increase by 54.4%-71.55% year-on-year

Zhongpet Co., Ltd. (002891) announced that in 2024, it is expected to achieve a net profit attributable to shareholders of listed companies of 360 million yuan to 400 million yuan, an increase of 54.4% to 71.55% year-on-year. During the reporting period, the company adhered to the core of its own brand building, wanpy naughty, New Zealand ZEAL Zhenzhi, and Toptrees led the continuous and steady development, the gross profit continued to increase, and the profitability level increased significantly, which promoted the company's overall profit to rise steadily, and the overseas business of its own brand maintained rapid development, and accelerated the construction of brand globalization.

Hualan Vaccine: Net profit in 2024 is expected to decrease by 70.93%-76.74% year-on-year

Hualan Vaccine (301207) announced that it is expected to achieve a net profit attributable to shareholders of listed companies of 200 million yuan to 250 million yuan in 2024, a year-on-year decrease of 76.74%-70.93%. In June 2024, the company adjusted the price of quadrivalent influenza vaccine products, and the prices of major products were reduced by more than 40%, in addition, in 2024, affected by multiple factors such as changes in public vaccination rates, declining vaccine market demand, and reduced sales, the company's business development and profitability were significantly impacted, resulting in a significant decline in the company's 2024 annual performance.

China Television Media: Net profit in 2024 is expected to decrease by 79% to 84% year-on-year

China Television Media (600088) released a performance forecast, and it is expected to achieve a net profit attributable to the owners of the parent company of 39 million yuan to 49 million yuan in 2024, a year-on-year decrease of 79% to 84%. In 2024, the operating profit of the company's film and television and tourism business segment will decrease slightly compared with the same period last year. Affected by the changes in the stock prices of listed companies held by the funds in which the company participates, the company's investment income decreased compared with the same period last year.

Sanyou Chemical: Net profit in 2024 is expected to decline by about 13% year-on-year

Sanyou Chemical (600409) announced that according to the preliminary calculation of the financial department, the company expects to achieve a net profit attributable to the owners of the parent company of about 490 million yuan in 2024, a decrease of about 76 million yuan compared with 566 million yuan in the same period last year, a year-on-year decrease of about 13%. The main reason for the decrease in the performance of this period is that due to the continuous expansion of production capacity in the soda ash and organic silicon industries, as well as the severe and complex external situation such as high raw material prices and insufficient downstream demand, the company's leading products showed a weak adjustment market, among which the soda ash segment decreased significantly year-on-year, and although the chemical fiber sector, chlor-alkali sector and organic silicon sector improved year-on-year, the profitability was still insufficient, resulting in a year-on-year decline in net profit attributable to the owners of the parent company in the reporting period.

InnoCare: It is expected to lose about 443 million yuan in 2024

InnoCare (688428) released a performance forecast, which is expected to achieve revenue of about 1.001 billion yuan in 2024, an increase of about 49% compared with the same period last year. The total operating income was about 1.01 billion yuan, an increase of about 37% compared with the same period last year. Net profit attributable to owners of the parent company was about 443 million yuan, a decrease of about 30% compared with the same period last year.

Furi Electronics: The net profit in 2024 is expected to lose 330 million yuan

Furi Electronics (600203) announced that after preliminary calculations by the financial department, it is expected that the net profit attributable to the owners of the parent company in 2024 will be -330 million yuan, and the net profit attributable to the owners of the parent company in the same period last year will be -286 million yuan. In 2024, due to the fierce competition in the industry and the price increase of key devices in the first half of 2024, the gross profit margin of consumer terminal products will decline.

Lanwei Medical: The net profit in 2024 is expected to lose 107 million yuan - 157 million yuan

Lanwei Medical (301060) announced that the net profit loss attributable to shareholders of listed companies is expected to be 107 million yuan to 157 million yuan in 2024, compared with a loss of 142 million yuan in the same period last year. During the reporting period, the long-aged accounts receivable of some of the company's testing business realized the collection, resulting in a significant decrease in the credit impairment loss accrued this year compared with the same period last year.

Heyuan Biotech: The net profit in 2024 is expected to lose 282 million yuan to 339 million yuan

Heyuan Biotechnology (688238) announced that the company expects to achieve a net profit attributable to the owners of the parent company of -339 million yuan to -282 million yuan in 2024, an increase of 154 million yuan to 211 million yuan compared with -128 million yuan in the same period last year. During the reporting period, the company's CDMO business continued to be affected by macro environmental changes, industrial conditions, downstream demand and other factors, and the price of executed orders was still at a historical low, while the first phase of the company's Lingang base has been fully put into operation, and it takes time to release production capacity, and operating costs such as depreciation and amortization costs, energy consumption costs, and administrative office expenses increased significantly year-on-year, resulting in a year-on-year decrease in operating gross profit and net profit of cell and gene therapy CDMO business during the reporting period.

Jinglun Electronics: The net profit in 2024 is expected to lose 34 million yuan to 43 million yuan

Jinglun Electronics (600355) announced that after the preliminary calculation of the company's financial department, it is expected that the net profit attributable to the owners of the parent company in 2024 will be -34 million yuan to -43 million yuan, with a loss of 43.3604 million yuan in the same period last year, and it is expected to achieve operating income of about 142 million yuan in 2024, and the operating income after deducting business income unrelated to the main business and income without commercial substance will be about 127 million yuan, less than 300 million yuan. It will trigger the delisting risk warning for the company's shares as stipulated in Article 9.3.2 (1) of the Rules Governing the Listing of Stocks on the Shanghai Stock Exchange, which stipulates that "the lower of the audited total profit, net profit or net profit after deducting non-recurring gains and losses in the most recent fiscal year is negative and the operating income is less than 300 million yuan, or the total profit, net profit or net profit after deducting non-recurring gains and losses in the most recent fiscal year after retrospective restatement is negative and the operating income is less than 300 million yuan". The company's shares may be subject to delisting risk alert after the disclosure of the 2024 annual report (add "*ST" before the company's stock abbreviation).

Lianhua Technology: In 2024, it is expected to achieve a net profit of 90 million yuan to 135 million yuan year-on-year

Lianhua Technology (002250) announced that it is expected to achieve a net profit attributable to shareholders of listed companies of 90 million yuan to 135 million yuan in 2024, compared with a loss of 465 million yuan in the same period last year, a year-on-year turnaround. In 2023, the company made an asset impairment provision of 238 million yuan for the related assets of the British subsidiary, and the company did not have the above matters in 2024.

Sifang New Materials: The net profit in 2024 is expected to lose 153 million yuan to 229 million yuan

Sifang New Materials (605122) announced that according to the preliminary calculation of the company's financial department, it is expected that the net profit attributable to shareholders of listed companies in 2024 will be -153 million yuan to -229 million yuan, compared with 12.9645 million yuan in the same period last year. Affected by the decline in the real estate industry, from January to November 2024, the area of new real estate construction in Chongqing fell by 23.6%, which greatly reduced the demand for commercial concrete products in Chongqing. On the same day, it was announced that in the fourth quarter of 2024, the company's commercial concrete output was 1,104,800 cubic meters, a year-on-year decrease of 23.56%; The output of asphalt concrete was 64,800 tons, a year-on-year increase of 138.24%. In 2024, the company's commercial concrete output will be 4,106,200 cubic meters, a year-on-year decrease of 26.51%; The output of asphalt concrete was 123,900 tons, a year-on-year decrease of 2.44%.

MGI: The net profit in 2024 is expected to be a loss of 554 million yuan to 670 million yuan

MGI (688114) announced that according to the company's preliminary calculation, it is expected to achieve a net profit attributable to the owners of the parent company of -670 million yuan to -554 million yuan in 2024, compared with a loss of 607 million yuan in the same period last year. During the reporting period, the company increased its market expansion efforts, resulting in an increase in related sales expenses. In addition, the fluctuation of foreign currency exchange rates such as the US dollar and the euro led to a year-on-year increase in the exchange loss of the company's foreign currency monetary items.

Remegen: The net profit in 2024 is expected to lose about 1.47 billion yuan

Remegen Biotechnology (688331) announced that according to the preliminary calculation of the financial department, it is expected that the operating income in 2024 will be about 1.715 billion yuan, which will increase by about 632 million yuan compared with the same period last year, an increase of about 58% year-on-year. It is expected that the net loss attributable to the owners of the parent company in 2024 will be about 1.47 billion yuan, which will reduce the loss by about 41 million yuan compared with the same period last year. During the year, the company's new drug R&D pipeline continued to advance, a number of innovative drugs were in the key trial research stage, R&D investment increased, and the sales revenue of tetanercept and vedicitumab increased rapidly, the gross profit margin of products continued to grow, and the sales expense ratio decreased significantly.

[Sign a big order].

Zhongzhong Technology: Signed a general contracting order contract of 367 million yuan

Zhongzhong Technology (603135) announced that the company signed the "General Contracting Order Contract for Electromechanical and Hydraulic Equipment of 1450mm Hot Rolled Coil Production Line" with Fuzhou Xingshenghe Industrial Co., Ltd., with a contract amount of 367 million yuan. The signing of this contract will have a positive impact on the company's 2025 annual results, bring stable cash flow to the company, help improve the financial position and enhance the company's profit.

Bomaike: signed a contract of 750 million yuan to 1 billion yuan

Bomec (603727) announced that the company signed a contract with STS VOF (hereinafter referred to as "STS") for the construction of the superstructure module of the offshore floating production, storage and offloading (FPSO), which will be deployed in the Suriname oilfield after the completion of the construction of the FPSO. The main scope of work covers the design, material procurement and construction of the FPSO upper module, with a contract value of 750 million yuan to 1 billion yuan, consisting of a fixed price part and the current estimated variable workload accounting amount. Conditions for the contract to take effect: January 2025.

[Increase or decrease in holdings].

Telink Micro: The National Fund plans to reduce its holdings of no more than 2% of the company's shares

Telink Micro (688591) announced that the 8.95% shareholder of the National Integrated Circuit Industry Investment Fund Co., Ltd. (hereinafter referred to as the "National Fund") plans to reduce the total number of shares of the company held by it by centralized bidding transactions within 3 months after 15 trading days, and the proposed reduction ratio does not exceed 2.00% of the company's total share capital.